{"entity":{"id":"idea-cost-trial-enrolment-cost-lever","kind":"idea","name":"Treat trial enrolment as a cost lever: the sponsor pays for the drug","aka":[],"tldr":"In a clinical trial the experimental drug is free to the patient and the payer, and since 2022 Medicaid must cover routine trial costs like Medicare and private plans do; pointing more patients to trials lowers bills as well as advancing science.","summary":"Fewer than one in ten adults with cancer join a trial, and cost concerns about routine care coverage are a documented barrier. The Clinical Treatment Act (effective January 2022) requires state Medicaid programmes to cover routine costs in qualifying trials, joining Medicare (since 2000) and Affordable Care Act plans. With the sponsor supplying the drug, a trial arm is often the cheapest way to receive a new therapy. Systematic trial matching at diagnosis, and payer navigators who present trials alongside coverage options, would turn a research goal into a cost tool.","asOf":"2026-09-10","links":[{"label":"Medicaid.gov: coverage of routine patient costs in clinical trials (Clinical Treatment Act)","url":"https://www.medicaid.gov/federal-policy-guidance/downloads/cib122921.pdf"},{"label":"Medicare.gov: Clinical research studies","url":"https://www.medicare.gov/coverage/clinical-research-studies"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["ai-trial-matching"],"targets":[],"drugs":[],"companies":[],"institutions":["nci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-trial-enrolment","b-drug-pricing","b-trial-diversity"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Routine trial matching with coverage counselling will double enrolment in participating practices and lower payer drug spend per enrolled patient by the cost of the investigational agent.","rationale":"The coverage law is now uniform across public payers; the remaining gap is awareness and matching effort.","test":"Practice-level pilot with enrolment rates, patient out-of-pocket costs and payer spend for enrolled versus matched non-enrolled patients.","maturity":"being-tested-at-scale","actor":"policy","cost":"small","horizonYears":2},"route":"/ideas/idea-cost-trial-enrolment-cost-lever/","neighbours":{"technology":[{"id":"ai-trial-matching","kind":"technology","name":"AI trial matching & clinical decision support","route":"/technologies/ai-trial-matching/"}],"institution":[{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"}],"bottleneck":[{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"},{"id":"b-trial-diversity","kind":"bottleneck","name":"Trials do not represent the people who get cancer","route":"/bottlenecks/b-trial-diversity/"},{"id":"b-trial-enrolment","kind":"bottleneck","name":"Trials enrol too few, too slowly","route":"/bottlenecks/b-trial-enrolment/"}]}}